A Phase II Study of Cabozantinib for Patients With Recurrent or Progressive Meningioma
Baptist Health South Florida
Summary
A Phase II Study of Cabozantinib for Patients with Recurrent or Progressive Meningioma
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria 1. Histologic (preferred) or radiologic diagnosis of meningioma. All World Health Organization (WHO) grades (I, II and III) are allowed. 2. All patients must have developed recurrent disease or progressive disease after receiving standard therapy (e.g., radiation or surgery) \> 6 months ago or have been deemed ineligible to receive these therapies. 3. Karnofsky Performance Status ≥ 50. 4. Adequate hematologic function: 1. Absolute Neutrophil Count ≥ 1.5 × 10\^9 / L without granulocyte colony-stimulating factor support. 2. Platelet Count ≥ 100 × 10\^9 / L without tran…
Interventions
- DrugCabozantinib
Cabozantinib tablets are supplied as film coated tablets containing cabozantinib malate equivalent to 20 mg and 60 mg of cabozantinib and contain microcrystalline cellulose, lactose anhydrous, hydroxypropyl cellulose, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate and Opadry® yellow. The 60 mg tablets are oval and the 20 mg tablets are round. Doses of 40 mg will comprise two 20-mg tablets. The starting dose for all participants is 60 mg per day by mouth. The study doctor may reduce a participant's dose to 40 mg per day, 20 mg per day, or 20 mg every other day depending on severity of side effects. The study doctor may also increase the dose back up to 60 mg per day if side effects improve.
Locations (3)
- Miami Cancer Institute at Baptist Health, Inc.Miami, Florida
- Memorial Sloan Kettering Cancer CenterNew York, New York
- Vanderbilt University Medical CenterNashville, Tennessee